Published in Br J Cancer on January 13, 2009
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 6.15
Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst (2001) 5.97
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst (2007) 4.11
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst (2007) 3.39
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Systematic overview of cost-utility assessments in oncology. J Clin Oncol (2000) 2.02
Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer (1991) 1.97
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst (2007) 1.97
Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol (1998) 1.74
Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol (2002) 1.68
Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst (2001) 1.48
Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol (2004) 1.47
Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. J Clin Oncol (2000) 1.43
Developing guidance for budget impact analysis. Pharmacoeconomics (2001) 1.40
Functional outcome after hip fracture in Japan. Clin Orthop Relat Res (1998) 1.36
Does mammographic density reflect ethnic differences in breast cancer incidence rates? Am J Epidemiol (2004) 1.30
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int (2004) 0.99
The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol (1993) 0.93
Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J (2000) 0.88
Inferior vena cava filter is a new additional therapeutic option to reduce mortality from acute pulmonary embolism. Circ J (2004) 0.88
The cost effectiveness of tamoxifen in the prevention of breast cancer. Am J Manag Care (1999) 0.86
The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw (2007) 0.85
Tamoxifen: an enduring star. J Natl Cancer Inst (2007) 0.83
The benefits and costs of tamoxifen for breast cancer prevention. Aust N Z J Public Health (2003) 0.82
Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. Breast Cancer Res Treat (1993) 0.82
Estimation of individualized probabilities of developing breast cancer for Japanese women. Breast Cancer (2003) 0.81
Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol (2001) 0.81
Chemoprevention: drug pricing and mortality: the case of tamoxifen. Cancer (2006) 0.79
Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes (Lond) (2005) 0.79
Cost-effectiveness of the bird's nest filter for preventing pulmonary embolism among patients with malignant brain tumors and deep venous thrombosis of the lower extremities. Support Care Cancer (2003) 0.78
Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective? Breast Cancer Res Treat (2005) 0.77
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res (2000) 3.86
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer (2001) 2.51
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst (1997) 1.87
An immunohistochemical study of developing glomeruli in human fetal kidneys. Kidney Int (2000) 1.69
Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res (1996) 1.39
Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer (2000) 1.36
Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother (2006) 1.31
A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis (2003) 1.30
Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer (2005) 1.28
Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer (2003) 1.24
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol (2000) 1.17
Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines. Thromb Haemost (2001) 1.16
Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey. Breast Cancer Res Treat (2011) 1.15
Alpha smooth muscle actin positive stromal cells in gastric carcinoma. J Clin Pathol (2002) 1.15
MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem Biophys Res Commun (2001) 1.13
Review of renal oncocytoma with focus on clinical and pathobiological aspects. Histol Histopathol (2003) 1.09
Clinical features of surgical resection for pulmonary metastasis from breast cancer. Eur J Surg Oncol (2008) 1.08
Interleukin-4 and breast cancer. Breast Cancer (2000) 1.08
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am (1999) 1.08
Cisplatin induces the proapoptotic conformation of Bak in a deltaMEKK1-dependent manner. Mol Cell Biol (2001) 1.07
Expression of CD9/motility-related protein 1 (MRP-1) in renal parenchymal neoplasms: consistent expression in papillary and chromophobe renal cell carcinomas. Hum Pathol (2001) 1.07
Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res (1995) 1.07
Distribution and role of CD34-positive stromal cells and myofibroblasts in human normal testicular stroma. Histol Histopathol (2004) 1.04
Natural killer cells in breast cancer cell growth and metastasis in SCID mice. Biomed Pharmacother (2005) 1.03
Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol (2003) 1.02
Somatic mutations of LKB1 and beta-catenin genes in gastrointestinal polyps from patients with Peutz-Jeghers syndrome. Cancer Res (2000) 1.01
Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother (2005) 1.00
Lack of CD34 positive stromal cells within angiomyomas (vascular leiomyomas). J Clin Pathol (2002) 0.99
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed Pharmacother (2005) 0.98
Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. J Biochem (2001) 0.98
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study). Breast Cancer Res Treat (2014) 0.98
Pulmonary adenocarcinoma with micropapillary component: an immunohistochemical study. Case report. APMIS (2005) 0.97
CD34 positive stromal cells in gastric adenocarcinomas. J Clin Pathol (2001) 0.96
Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br J Cancer (1997) 0.95
Circulating angiogenesis regulators in cancer patients. Int J Biol Markers (2001) 0.94
Significance of membrane type 1 matrix metalloproteinase expression in breast cancer. Jpn J Cancer Res (1999) 0.94
Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res (2000) 0.93
Lack of vascular adventitial fibroblastic cells in tumour stroma of intestinal-type and solid-type gastric carcinomas. J Clin Pathol (2004) 0.92
Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res (2001) 0.92
Bilateral ischemic necrosis of the tongue due to disseminated intravascular coagulation. Int J Oral Maxillofac Surg (2008) 0.92
The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol (2012) 0.92
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat (2013) 0.91
Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep (1998) 0.91
The distribution and role of myofibroblasts and CD34-positive stromal cells in normal pancreas and various pancreatic lesions. Histol Histopathol (2004) 0.89
Adenoid basal carcinoma of the uterine cervix: a case report with ultrastructural findings. Med Electron Microsc (2000) 0.89
The distribution pattern of myofibroblasts in the stroma of human bladder carcinoma depends on their invasiveness. Histol Histopathol (2006) 0.89
Diagnostic pitfall of D2-40 in adenomatosid tumour. Histopathology (2007) 0.88
Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer (1991) 0.87
Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res (1999) 0.87
Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. Oncology (2001) 0.87
Clinical significance of plasma nucleosome levels in cancer patients. Int J Oncol (2001) 0.87
Goblet cell carcinoid of the appendix: Investigation of the expression of beta-catenin and E-cadherin. Pathol Int (2001) 0.87
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer. Biomed Pharmacother (2005) 0.85
Response to octreotide of intestinal pseudoobstruction and pneumatosis cystoides intestinalis associated with progressive systemic sclerosis. Intern Med (1993) 0.85
Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene. Cell Death Differ (2000) 0.85
The distribution of CD34-positive stromal cells and myofibroblasts in colorectal carcinoid tumors. Histol Histopathol (2005) 0.85
Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients. Oncol Rep (1998) 0.84
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. Ann Oncol (2003) 0.84
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. Cancer Chemother Pharmacol (2014) 0.84
Different features of angiogenesis between ovarian and breast carcinoma. Cancer Lett (2001) 0.83
Circulating levels of endostatin in cancer patients. Oncol Rep (2001) 0.83
High molecular weight caldesmon positive stromal cells in the capsule of thyroid follicular tumours and tumour-like lesions. J Clin Pathol (2002) 0.83
Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients. Int J Oncol (1998) 0.82
Rapid induction of hepatocyte growth factor by heparin. Lancet (1994) 0.82
Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg (1992) 0.82
Serum lipid profiles in patients receiving endocrine treatment for breast cancer--the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial. Biomed Pharmacother (2005) 0.82
Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol (2003) 0.82
Current directions for COX-2 inhibition in breast cancer. Biomed Pharmacother (2005) 0.81
Appearance of denuded hepatic stellate cells and their subsequent myofibroblast-like transformation during the early stage of biliary fibrosis in the rat. Med Electron Microsc (2000) 0.81
Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res (1998) 0.81
Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients. Biomed Pharmacother (2006) 0.81
Tumor angiogenesis, macrophages, and cytokines. Adv Exp Med Biol (2000) 0.81
Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients. Support Care Cancer (2011) 0.81
Fascin-positive dendritic cells and fibroblastic reticulum cells build a framework of T-cell areas in lymph nodes. Virchows Arch (2003) 0.80
Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis. Eur J Pharmacol (1993) 0.80
Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies. Oncology (2000) 0.80
The complementary role of beta-catenin in diagnosing various subtypes of renal cell carcinomas and its up-regulation in conventional renal cell carcinomas with high nuclear grades. Oncol Rep (2001) 0.80
Expression of human epidermal growth factor and its receptor in esophageal cancer. Jpn J Surg (1990) 0.80
The participation of myofibroblasts in the capsular formation of human conventional and chromophobe renal cell carcinomas. Histol Histopathol (2005) 0.80
Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol. Jpn J Cancer Res (1999) 0.79
Review of collecting duct carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol (2002) 0.79
Anaplastic carcinoma of the pancreas with rhabdoid features. Pathol Int (2000) 0.79
Cytokeratin-positive subserosal myofibroblasts in gastroduodenal ulcer; another type of myofibroblasts. Histol Histopathol (2006) 0.78
The distribution of myofibroblasts and CD34-positive stromal cells in normal renal pelvis and ureter and their cancers. Histol Histopathol (2006) 0.78
Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis. Oncol Rep (2001) 0.78
Power Doppler sonography of breast masses: correlation of Doppler spectral parameters with tumor angiogenesis and histologic growth pattern. J Ultrasound Med (2000) 0.78
Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. Int J Oncol (2001) 0.78
The disappearance of CD34-positive and alpha-smooth muscle actin-positive stromal cells associated with human intra-uterine and tubal pregnancies. Histol Histopathol (2004) 0.78
Prediction of the effect of 5'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients. Oncol Rep (1996) 0.77
Immunohistochemical identification of intracytoplasmic lumens by cytokeratin typing may differentiate renal oncocytomas from chromophobe renal cell carcinomas. Histol Histopathol (2004) 0.77
[Expression of the epidermal growth factor receptor in esophageal cancer]. Gan No Rinsho (1989) 0.77
The appearance of myofibroblasts and the disappearance of CD34-positive stromal cells in the area adjacent to xanthogranulomatous foci of chronic cholecystitis. Histol Histopathol (2005) 0.77
Mesangial myofibroblastic transformation in steroid-dependent minimal change nephrotic syndrome. Med Electron Microsc (2000) 0.77
Review of mucinous tubular and spindle-cell carcinoma of the kidney with a focus on clinical and pathobiological aspects. Histol Histopathol (2005) 0.77
Malignant phyllodes tumor of the breast with expression of osteonectin and vinculin. Pathol Int (2001) 0.77
Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma. Appl Immunohistochem Mol Morphol (2001) 0.77
Involvement of the nipple in early carcinoma of the breast. Surg Gynecol Obstet (1989) 0.76
Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice. Drugs Exp Clin Res (1996) 0.76
Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique. Breast Cancer Res Treat (2012) 0.76